On 12 May 2026, at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye, groundbreaking findings from the Phase 3a REDEFINE-1 trial were presented, showcasing the potential of Novo Nordisk’s fixed-dose combination of cagrilintide 2.4mg and semaglutide 2.4mg (CagriSema) for adults grappling with obesity. The trial focused on individuals defined by a Body Mass Index (BMI) of ≥30 kg/m² or ≥27 kg/m² with at least one obesity-related complication. While contemporary pharmacotherapies have made significant strides in achieving substantial weight loss, a persistent challenge has been the risk of concomitant muscle mass loss, a phenomenon that carries potential implications for physical function and the increased likelihood of developing sarcopenia. This critical analysis aimed to rigorously evaluate muscle strength, meticulously assess changes in body composition using dual-energy X-ray absorptiometry (DXA), and critically examine the intricate correlation between body composition metrics and observed physical function.
CagriSema represents a novel, once-weekly subcutaneous fixed-dose co-formulation that synergistically combines cagrilintide, a long-acting amylin analogue that exerts its effects via the calcitonin receptor, with semaglutide, a well-established glucagon-like peptide-1 receptor agonist (GLP-1RA). This innovative therapeutic agent is currently undergoing pre-registration for obesity and overweight indications in the United States. Its global Phase III investigation is actively underway for obesity, overweight, and type 2 diabetes (T2D). Furthermore, CagriSema is in Phase II evaluation for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and diabetic peripheral neuropathy, highlighting its broad therapeutic potential.
The rigorous REDEFINE-1 trial was designed as a comprehensive 68-week, randomized, double-blind, placebo- and active-controlled, multi-center study. It enrolled a substantial cohort of 3,417 participants who were allocated in a carefully determined 21:3:3:7 ratio. This allocation ensured adequate representation across the treatment arms: once-weekly subcutaneous CagriSema 2.4mg/2.4mg, semaglutide 2.4mg alone, cagrilintide 2.4mg alone, or a placebo. All treatment regimens were administered as an adjunct to a structured reduced-calorie diet and an intensified physical activity program. To specifically assess muscle strength, the sit-to-stand (STS) test was employed at both baseline and the 68-week mark in a subset of 1,038 participants. Furthering the depth of the analysis, 252 of these participants underwent DXA scans to provide precise measurements of bone mineral density, fat mass, and lean soft tissue (LST). A detailed post-hoc analysis was subsequently conducted to investigate the correlation between these detailed body composition parameters and physical function scores derived from two widely recognized patient-reported outcome instruments: the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQoL-Lite-CT) and the SF-36v2 Health Survey Acute (SF-36v2). All reported results pertain to the trial product estimate, ensuring a focused evaluation of CagriSema’s efficacy.
Key Findings Presented at ECO 2026
The findings, presented at the esteemed ECO 2026 by Eric Ravussin, PhD, a distinguished Professor of diabetes and metabolism and the director of the Human Translational Physiology Laboratory and Nutrition Obesity Research Center at Pennington Biomedical Research Center in Baton Rouge, Louisiana, revealed compelling results. CagriSema 2.4mg/2.4mg demonstrated the most significant weight reduction at the 68-week endpoint within the DXA subgroup, achieving an impressive mean loss of -23.9%. This far surpassed the results observed with semaglutide 2.4mg (-16.6%), cagrilintide 2.4mg (-15.0%), and the placebo group (-2.8%).
Crucially, the substantial weight loss achieved with CagriSema was predominantly driven by a reduction in fat mass. Specifically, 66.9% of the total weight lost was attributable to fat mass, while 33.1% was accounted for by lean soft tissue. This favorable pattern of fat-predominant weight loss was consistent across all active treatment arms. Semaglutide treatment resulted in 69.7% of weight loss from fat mass, and cagrilintide treatment showed 62.9% of weight loss from fat mass. This suggests that both components of the combination therapy contribute to a healthier body composition profile.
A particularly noteworthy observation emerged from the analysis of participants who achieved a remarkable ≥30% body weight loss with CagriSema. In this subgroup, the proportion of fat mass within their total body weight decreased significantly from 46.3% to 33.2%. Concurrently, the proportion of lean soft tissue within their total body weight increased from 51.3% to 63.2%. These data unequivocally confirm an improvement in body composition at higher levels of weight loss, a critical factor for long-term health and metabolic well-being.
Beyond body composition, CagriSema demonstrated a significant positive impact on physical function. Participants treated with CagriSema showed statistically significant improvements compared to placebo on both the IWQoL-Lite-CT and SF-36v2 patient-reported outcome measures. This indicates a tangible enhancement in the quality of life and functional capacity of individuals receiving the combination therapy. Furthermore, and critically, CagriSema did not lead to a decrease in muscle strength relative to the placebo group, directly addressing the long-standing concern of muscle mass loss associated with aggressive weight reduction strategies.
Background and Context of the REDEFINE-1 Trial
The REDEFINE-1 trial is a cornerstone in the development of CagriSema, building upon prior research into the individual agents and their synergistic potential. Amylin analogues, like cagrilintide, mimic the action of amylin, a hormone released by pancreatic beta cells that helps regulate postprandial glucose and promotes satiety. GLP-1 receptor agonists, such as semaglutide, are known for their potent effects on appetite regulation, glucose homeostasis, and weight loss. The combination of these two mechanisms of action in CagriSema was hypothesized to offer a more profound and sustained effect on weight management.
The 33rd European Congress on Obesity serves as a premier platform for presenting cutting-edge research in the field of obesity and metabolic diseases. Held annually, it brings together leading scientists, clinicians, and researchers to share their latest findings, discuss emerging trends, and foster collaborations. The presentation of REDEFINE-1 trial data at this congress underscores the significance of these findings within the global scientific community dedicated to tackling the obesity epidemic.
Implications for Obesity Treatment Landscape
The results from REDEFINE-1, particularly the demonstration of fat-predominant weight loss and preserved muscle strength, hold significant implications for the future of obesity pharmacotherapy. For years, the medical community has grappled with the trade-off between achieving substantial weight loss and maintaining muscle mass, which is vital for metabolic health, mobility, and overall quality of life. The observed preservation of muscle strength with CagriSema, even amidst significant weight reduction, addresses this critical unmet need.
Key opinion leaders interviewed by GlobalData, a leading data and analytics company, have recognized the formidable competitive potential of CagriSema. They suggest it could directly challenge the market dominance of existing therapies like semaglutide alone and potentially achieve weight loss outcomes comparable to other advanced treatments such as tirzepatide, a dual GLP-1/GIP receptor agonist. This competitive positioning suggests that CagriSema could significantly reshape the dynamics of the overweight and obesity market, offering a new and potentially more effective therapeutic option for a broad patient population.
Broader Impact and Future Outlook
While an overall absolute reduction in lean soft tissue (LST) was observed with CagriSema, as is typical with significant weight loss across various interventions, the critical finding is the increase in the proportion of LST relative to total body weight post-weight loss. Coupled with the preservation of muscle strength, this indicates that the therapy not only facilitates weight reduction but does so in a manner that prioritizes lean mass preservation and functional capacity. These findings collectively reinforce CagriSema’s potential as a dual-mechanism therapy capable of delivering substantial, fat-predominant weight loss while concurrently maintaining vital physical function. This strengthens its promising position within the evolving landscape of overweight and obesity management.
The global development pipeline for obesity treatments remains robust, reflecting the ongoing urgent need for effective interventions. According to GlobalData’s Pharma Intelligence Center, there are currently 48 Phase III candidates, 112 Phase II candidates, and 158 Phase I candidates for overweight and obesity in various stages of development worldwide. CagriSema’s promising Phase III results place it at the forefront of this pipeline, with regulatory submissions anticipated.
The successful development and approval of CagriSema could represent a significant advancement in the fight against obesity, offering a more comprehensive approach that addresses both weight reduction and the preservation of essential physiological functions. The continued investigation into its efficacy and safety across various patient populations, including those with MASH and diabetic peripheral neuropathy, will be crucial in fully realizing its therapeutic potential. The journey from trial presentation to widespread clinical adoption is often complex, but the data emerging from REDEFINE-1 offer a compelling glimpse into a future where managing obesity is not only about shedding pounds but also about enhancing overall health and functional well-being.
Leave a Reply